<DOC>
	<DOC>NCT02798328</DOC>
	<brief_summary>Observational trial to evaluate the effectiveness of the TEG6s DOAC cartridge to detect and classify the presence of DOAC drugs in a subject.</brief_summary>
	<brief_title>Direct Oral Anticoagulant Assay Detection &amp; Classification Study for the TEG 6S System</brief_title>
	<detailed_description />
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>â‰¥ 18 years old DOAC administered for a minimum of 7 days Genetic Bleeding disorders. Known or subsequently discovered inherited defects of coagulation (e.g. hemophilia or Von Willebrand disease) Not known when last two DOAC doses were administered prior to blood draw DOAC first administered (or resumed after temporary cessation) less than 7 days prior to blood draw DOAC dosage outside of manufacturer's recommended range (e.g. study subject with renal impairment and supratherapeutic dose) Heparin or LMWH administered within 7 days prior to blood draw On any medications known to affect coagulation status and listed below Bruising, wounds or scarring in the area of venipuncture List of medications known to affect coagulation status 1. Vitamin K Antagonists [VKAs] Warfarin Phenprocoumon Acenocoumarol Tecarfarin [ATI5923] Phenindione Anisindione Elinogrel Vorapaxar Atopaxar 2. Heparin and Heparins Unfractionated Heparin [UFH] LMWH Fondaparinux Idraparinux Danaparoid 3. Vasopressin Analogues DDAVP 4. Direct Thrombin [IIa] Inhibitors Hirudin Lepirudin Bivalirudin Argatroban 5. Defibrinating Agents Ancrod</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>